0001193125-26-224289
SEC filingTempest Therapeutics reported a larger operating and net loss in Q1 FY2026 versus Q1 FY2025, reflecting continued investment in advancing its pipeline while exploring strategic alternatives; diluted EPS improved modestly due to share count changes, not profitability.
The company reported an operating loss of $27.7 million for Q1 FY2026, compared to $10.9 million in Q1 FY2025. This widening reflects the ongoing reality that Tempest Therapeutics remains in the pre-revenue, clinical-stage phase of development. As stated in Management’s Discussion, the company expects to generate substantial operating losses for the foreseeable future until it completes development and obtains regulatory approval for a product candidate. The magnitude of the loss is consistent with the scale of investment required to advance oncology therapeutics through clinical trials, including regulatory support and contract manufacturing.
Net income for the quarter was $27.7 million, essentially equal to operating income, indicating minimal non-operating activity. Diluted EPS was $-2.53, an improvement from $-3.16 in the prior-year quarter. This change reflects adjustments to the weighted-average share count rather than any inflection in profitability or cost structure. Management has not provided updated guidance on EPS drivers beyond reiterating that losses will persist until commercialization.
Net cash used in operating activities totaled $7.6 million, a slight improvement from $8.0 million in Q1 FY2025. Capital expenditures were $0, resulting in free cash flow of $-7.6 million—identical to operating cash flow. This pattern reinforces management’s statement that current cash use is focused on sustaining core infrastructure: headcount, leases, and overhead—while evaluating strategic alternatives. There are no material non-cancelable purchase commitments, and the company operates under cancelable, purchase-order-based contracts with service providers.
While the company implemented cost reductions in 2025, it emphasizes that it has finite cash resources available to fund operations. Management expects R&D expenses to increase in the future as product candidates advance into and through clinical trials—a process requiring significant investment in trials, regulatory support, and manufacturing. No new funding arrangements, balances, or liquidity triggers are disclosed in the authoritative financial packet for this filing period. The narrative remains anchored in the structural reality of late-stage biotech development: sustained losses, strategic evaluation, and capital-constrained execution.